A venture capital investment firm based in the US that is supported by a family office who has invested in healthcare operating companies and real estate for over 30 years, seeks to invest in opportunities that align with their strategic interests. Investments in healthcare have included skilled nursing facilities, rehabilitation therapy, institutional pharmacy, hospice, mental health tech, healthcare tech, and home health. The firm looks to work with early stage companies where they can leverage their operating platform.  As a private investor, the firm has a very flexible horizon and mandate – investment size can greatly vary on a deal-by-deal basis. The firm has about 20 companies in their its portfolio, and invests all across the USA.

The firm has a robust portfolio that ranges from healthcare to technology to consumer products. While the firm has a broad interest in healthcare, the firm is most interested in technologies that can leverage the firm’s operating platform and resources. The firm’s portfolio companies include workforce transformation, nurse staffing, medical billing, and Fintech that is focused on the healthcare sector, medical billing, and more. The firm also has a strong interest in technologies dedicated to mental & behavioral health. The firm is opportunistic in terms of stage of development. The firm does not consider therapeutics opportunities.

The firm seeks to partner with smart, thoughtful founders with a true commitment in their ideas. The firm is a hands-on investor and seeks to have an active role in their portfolio companies. As mentioned above, the firm is able to leverage its resources to support pilots and enable companies to test new ideas. The firm can also support companies in enhancing their business models, implementing scale through partnerships, and share their own experiences in developing world-class brands.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm that is a division of a Japan-based manufacturer of various goods including pharmaceuticals, chemicals, etc. – one of the largest privately held companies in Japan – is actively looking for global partnering opportunities that complement the firm’s current research pipeline. Types of partnerships can include in-licensing, co-development, co-commercialization, and potentially more. Though the firm is capable of making investments and may expand upon their methods of partnering with early-stage companies, the firm does not currently have a dedicated venture capital fund.

The firm is primarily interested in therapeutics that complement the firm’s current research pipeline which includes assets in cardiovascular disease, metabolic disease, peripheral arterial disease, and pain management. The firm is interested in novel compounds that they can develop through proof of concept, and is generally stage agnostic. While the firm has historically focused on small molecules, the firm has a growing interest in antibodies and cell therapies. In addition, the firm is strongly interested in platform technologies.

The firm does not have specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm that was founded in 2020 with general partners based in the USA has a $100M USD fund dedicated to early-stage life science ventures from Seed to Series A.  The initial size of investment ranges from $1-5M and the firm seeks to invest in up to 10-12 early-stage life science companies worldwide.

The firm operates under a model that differs from traditional venture capital. As a way of de-risking, the firm works closely with a CRO that provides services and guidance on clinical translation and regulatory approval to therapeutics and medical device portfolio companies. The firm also works very closely with founders. As a critical criterion, the firm prefers to assign a highly experienced CEO to their portfolio company as they strongly believe in the importance of the management team. Also, the firm mostly exits through licensing to large pharma, medtech, or services companies. They are opportunistic about other exit strategies such as IPO.

The firm focuses on therapeutics, diagnostics, and digital health. The firm will not consider digital health. For therapeutics, pre-IND products of all modalities are considered. Within diagnostics, all modalities with proof of concept are considered. The firm will consider opportunities in any indication area.

The firm prefers asset-centric products and focuses on the scientific merits of the product or technology. The firm has a strict vetting process done by a highly experienced team and prefers companies with IP in place. The firm acts as a lead and co-investor and will require board seating.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage investment and development firm located in the US has more than $300 million in assets and operates under an “Evergreen” structure. The firm is flexible in investment size and structure, but prefer initial investments in the $1-5M range and the firm reserves additional funds for the subsequent funding of successful companies.

The firm invests in medical devices and research tools. For medical devices, the firm prefers those that can be approved under PMA guidelines. For research tools, the firm invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management/execution team. The firm prefers to invest in companies in the U.S., but will consider opportunities in Europe, Israel and Australia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Taiwan solely invests in early stage medical technology ventures. The firm currently manages a fund focused on medtech investments. The firm focuses on Series A and B rounds and looks to allocate USD 500K to 3 million per round with reserved follow-on investments. The firm will target companies in Taiwan, Israel, and the US. The firm is actively seeking new investments.

The firm looks to invest in innovative medical devices. The firm seeks breakthrough products that are clearly differentiated and superior to existing products. The firm is opportunistic in terms of subsectors and will consider devices in Class I, II, and III. The firm is indication agnostic but only seeks large market opportunities of at least $500 million in targeted annual revenue.

The firm seeks a strong and experienced management team and typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor and venture builder invests in pre-clinical therapeutics companies, frequently taking a majority stake and playing an active role in the company’s development. The firm is open to all therapeutic types and indications, currently they have a particular interest in immunology and oncology. The firm will generally invest $1-5M, and will invest globally, with previous investments in North America, Europe, and Israel.

The firm is interested only in therapeutics companies, but will consider all types of therapeutics in all indications. The firm invests from discovery to preclinical stage and will support companies development efforts.

The firm prefers to lead and take a majority stake in their portfolio companies, and then act as a venture builder. The firm is interested only in companies that have strong IP portfolios.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture capital of a manufacturing company based in Asia makes 50% of their investments in life science and healthcare and has had multiple successful exits in the past. The firm is actively looking for early-stage investment opportunities in the space. The firm prefers to invest in earlier rounds and the sweet spot is Seed to Series B. The firm is an evergreen fund. Typical initial check size ranges from $250k to half a million, but the firm is able to allocate more depending on the deal size. The firm is open to other capital structures, such as convertible notes or SAFE. The firm typically co-invests more than leads but is open to both, and it seeks opportunities globally.

The firm is most interested in therapeutics, diagnostics, medical devices and digital health and biotech R&D Services (CDMO). The firm is agnostic to subsectors and indications. Some areas of interest include technologies that support clinical study or help identify new markers or targets. In terms of stages of development, the firm is open to pre-clinical stage companies, or even companies that are in the “idea phase” as long as the technology is sound and there is some proof of concept.

There is no specific company and management team requirement. The firm will consider a board seat or observer seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.